Who are Proactive TDM-based dosing of ixekizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taltz, Cosentyx, Vunakizumab (IL-17A inhibitor), Subcutaneous injection of Secukinumab, Secukinumab Auto-Injector, Secukinumab 150 milligram [Cosentyx].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/proactive-tdm-based-dosing-of-ixekizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Proactive TDM-based dosing of ixekizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-17A inhibitor; monoclonal antibody. Area: Immunology.

marketed IL-17A inhibitor; monoclonal antibody IL-17A Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab) — University Hospital, Ghent. Ixekizumab is an IL-17A inhibitor that blocks interleukin-17A signaling to reduce inflammatory responses in autoimmune conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Proactive TDM-based dosing of ixekizumab TARGET	Proactive TDM-based dosing of ixekizumab	University Hospital, Ghent	marketed	IL-17A inhibitor; monoclonal antibody	IL-17A
Taltz	ixekizumab	Eli Lilly	marketed	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Vunakizumab (IL-17A inhibitor)	Vunakizumab (IL-17A inhibitor)	Fujian Cancer Hospital	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Subcutaneous injection of Secukinumab	Subcutaneous injection of Secukinumab	Peking Union Medical College	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A (Interleukin-17A)
Secukinumab Auto-Injector	Secukinumab Auto-Injector	University of Pennsylvania	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Secukinumab 150 milligram [Cosentyx]	Secukinumab 150 milligram [Cosentyx]	Professor Mikkel Østergaard	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-17A inhibitor; monoclonal antibody class)

University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Proactive TDM-based dosing of ixekizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/proactive-tdm-based-dosing-of-ixekizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab